Payment overview · 2025
General Payments
$53,623.12
117 reported records · 13 companies
Healthcare provider profile · identity verified
Adam Jay Teichman, DPM
Podiatric Medicine & Surgery Service Providers|Podiatrist|Foot & Ankle Surgery · ALLENTOWN, PA · NPI 1043203656
Verified facts
What the public records show
CMS Open Payments records show Adam Jay Teichman, DPM received $53,623.12 in general payments during 2025 across 117 reported records.
Averitas Pharma Inc. accounted for 64.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Qutenza.
Averitas Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QUTENZA as an associated drug or biological on 11743 records involving 7078 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Qutenza by this doctor in 2024.
GRT US Holding, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QUTENZA as an associated drug or biological on 12 records involving 12 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Qutenza by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $34,561.13 | 64.5% | 51 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $16,939.69 | 31.6% | 24 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $678.23 | 1.3% | 14 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $280.80 | 0.5% | 5 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $279.50 | 0.5% | 6 | 2025 |
| GRT US Holding, Inc. | Unresolved — no canonical attribution shown | $211.17 | 0.4% | 1 | 2025 |
| Next Science LLC | Unresolved — no canonical attribution shown | $171.34 | 0.3% | 2 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $148.28 | 0.3% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $140.06 | 0.3% | 8 | 2025 |
| Stability Biologics, LLC | Unresolved — no canonical attribution shown | $135.00 | 0.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $39.21 | 0.1% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $24.49 | 0.1% | 1 | 2025 |
| Bone Support Inc. | Unresolved — no canonical attribution shown | $14.22 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Honoraria | $22,055.00 | 8 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,222.50 | 11 |
| Travel and Lodging | $8,002.61 | 38 |
| Food and Beverage | $3,343.01 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc., GRT US Holding, Inc. | $34,772.30 | 52 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $16,811.57 | 22 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $446.25 | 6 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $335.92 | 2 | 2025 |
Source payment records
|
|||||
| AUGMENT INJECTABLE Normalized: augment injectable |
Device | Stryker Corporation | $246.93 | 3 | 2025 |
Source payment records
|
|||||
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $240.00 | 1 | 2025 |
Source payment records
|
|||||
| NOVACHOR Normalized: novachor |
Medical Supply | Organogenesis Inc. | $240.00 | 1 | 2025 |
Source payment records
|
|||||
| NUSHIELD Normalized: nushield |
Medical Supply | Organogenesis Inc. | $240.00 | 1 | 2025 |
Source payment records
|
|||||
| OASIS MICRO Normalized: oasis micro |
Device | Smith+Nephew, Inc. | $191.46 | 2 | 2025 |
Source payment records
|
|||||
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $189.30 | 3 | 2025 |
Source payment records
|
|||||
| PROSTEP MICA Normalized: prostep mica |
Device | Stryker Corporation | $178.13 | 3 | 2025 |
Source payment records
|
|||||
| BlastX Normalized: blastx |
Device | Next Science LLC | $171.34 | 2 | 2025 |
Source payment records
|
|||||
| Xperience Normalized: xperience |
Device | Next Science LLC | $171.34 | 2 | 2025 |
Source payment records
|
|||||
| STRAVIX PL Normalized: stravix pl |
Biological | Smith+Nephew, Inc. | $161.53 | 4 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $148.28 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $148.28 | 2 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $146.91 | 1 | 2025 |
Source payment records
|
|||||
| ORTHOLOC 2 LAPIFUSE Normalized: ortholoc 2 lapifuse |
Device | Stryker Corporation | $144.26 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $140.06 | 8 | 2025 |
Source payment records
|
|||||
| RENASYS TOUCH Normalized: renasys touch |
Device | Smith+Nephew, Inc. | $137.80 | 1 | 2025 |
Source payment records
|
|||||
| OASIS Normalized: oasis |
Device | Smith+Nephew, Inc. | $101.83 | 3 | 2025 |
Source payment records
|
|||||
| INNOVABURN Normalized: innovaburn |
Device | ConvaTec Inc. | $90.20 | 3 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $39.49 | 5 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $39.21 | 1 | 2025 |
Source payment records
|
|||||
| SIMPLIMAX Normalized: simplimax |
Medical Supply | Organogenesis Inc. | $32.20 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX MESH Normalized: stravix mesh |
Biological | Smith+Nephew, Inc. | $30.32 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $24.49 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $24.49 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $24.49 | 1 | 2025 |
Source payment records
|
|||||
| CERAMENT G Normalized: cerament g |
Device | Bone Support Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| CERAMENTBONE VOID FILLER Normalized: ceramentbone void filler |
Device | Bone Support Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| QUTENZA qutenza |
2025 | Qutenza | 2024 | 21 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Averitas Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | QUTENZA open payments reported associated product |
CMS Open Payments — General Payments 11743 supporting records · 7078 recipient NPIs · example record 1248543069 |
Qutenza · 2024 Exact normalized brand match · 1 Part D row |
21 | 11 |
| GRT US Holding, Inc. Exact reporting entity; no affiliate inference |
2025 | QUTENZA open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 12 recipient NPIs · example record 1184307623 |
Qutenza · 2024 Exact normalized brand match · 1 Part D row |
21 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Methylprednisolone | Methylprednisolone | 37 | 35 |
| Gabapentin | Gabapentin | 29 | 12 |
| Meloxicam | Meloxicam | 28 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 23 |
| Lidocaine | Lidocaine | 21 | suppressed |
| Qutenza | Capsaicin/Skin Cleanser | 21 | 11 |
| Ciclopirox | Ciclopirox | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 11 |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $53,623.12 · 117 records | Averitas Pharma Inc. | AFFINITY, APLIGRAF, AUGMENT INJECTABLE, BlastX, CERAMENT G, CERAMENTBONE VOID FILLER, COLLAGENASE SANTYL, Flector, GRAFIX PL, INNOVABURN, INNOVAMATRIX AC, Kerecis GraftGuide, Kerecis SurgiClose, Licart, NOVACHOR, NUSHIELD, OASIS, OASIS MICRO, ORTHOLOC 2 LAPIFUSE, PROSTEP MICA, PURAPLY WOUND MATRIX, QUTENZA, RENASYS TOUCH, SIMPLIMAX, STRAVIX, STRAVIX MESH, STRAVIX PL, Senza, Tirosint, WaveWriter Alpha Prime 16, Xperience | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Qutenza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Averitas Pharma Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error